Healthy Young AdultsNEUROACTIVENCT07032168
Lifestyle, Fitness, and Plasma Biomarkers in Healthy Young Adults
An observational study of Healthy Young Adults, run by European University Miguel de Cervantes at 1 site in Spain.
Trial summary
Lifestyle play a key role in modulating brain health by directly influencing a number of key biological processes, such as neuroplasticity, neurogenesis, and regulation of biomarkers associated with cognitive decline. Read more about this study
- Who is it for?
- Ages 18 to 24 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Young Adults
- How many people
- 31 participants
- Where
- 1 siteSpain
- Study dates
- 16 Jun 2025to 31 Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 24 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Healthy young adults, between 18 and 24 years old.
The following inclusion criteria are established:
- Age between 18 and 24 years.
- Not have chronic or neurodegenerative diseases.
- Not be on pharmacological treatment that affects the central nervous system or metabolism.
The exclusion criteria for participants:
- Medical or traumatological condition that makes it impossible to practice physical exercise.
- Musculoskeletal injury within 6 months prior to the first visit to the laboratory.
- Recent surgery (<3 months).
- Have a medical condition in which physical activity is contraindicated (assessed with the Physical Activity Predisposition Questionnaire (PARQ+).
Trial locations and contacts
1 site in 1 country.
Spain1 site
Miguel de Cervantes European University
Valladolid, Valladolid, 47012
About this study
Official title: Influence of Lifestyle Factors, Cardiorespiratory Fitness, and Body Composition on Plasma BDNF and pTau217 Levels and Cognitive Function in Healthy Young Adults
Lifestyle play a key role in modulating brain health by directly influencing a number of key biological processes, such as neuroplasticity, neurogenesis, and regulation of biomarkers associated with cognitive decline. Factors such as physical activity, diet, sleep quality, stress management, and body composition have been shown to have a significant impact on neuroprotection and cognitive performance. These factors not only contribute to maintaining metabolic and functional balance in the body, but are also linked to the expression of biomarkers such as brain-derived neurotrophic factor (BDNF) and Tau protein phosphorylated at the amino acid threonine 217 (PTau217), which are essential for the maintenance of neuronal health and the prevention of neurodegenerative diseases. In this sense, a healthy lifestyle, characterized by regular physical activity, a balanced diet, good quality sleep, low stress levels and adequate body composition, can act as a protective factor against cognitive decline from early stages of life.
- Conditions
- Healthy Young Adults
- Keywords
- Neuroplasticity, Lifestyle, Healthy young adults, Plasma biomarkers
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthy young adults | Healthy young adults (18-24 years old) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma biomarkers
Plasma concentrations of BDNF and pTau217 will be assessed using ELISA kits. Fasting venous blood samples will be collected by a qualified nurse from the antecubital vein into EDTA-treated vacutainers and centrifuged at 1500g for 10 minutes. Plasma will then undergo a second centrifugation at 2500g for 15 minutes and be stored in cryogenic vials at -80ºC. BDNF will be measured using the Human/Rat BDNF ELISA Kit (Proteintech Europe; sensitivity: 0.1 pg/mL; range: 12.5-800 pg/mL). PTau217 will be measured using the Human Phosphorylated Tau 217 ELISA Kit (GenoChem World; sensitivity: 0.1 pg/mL; range: 0.8-40 pg/mL).
Measured: Baseline
Secondary outcomes (19)
Physical activity levels
An accelerometer (ActiGraph GT3X, Actigraph Corporation, Pensacola, FL) will be provided to all participants one week prior to the assessments to monitor physical activity levels during all waking hours, except during the shower or bath. Registration will take place over a seven-day period, including at least three weekdays (Monday through Friday) and two days during the weekend. The accelerometer will be positioned on the right hip of each participant through the use of an elastic belt. Their position will be reviewed before and after the registration period and participants will be provided with a diary to indicate the hours of use.
Measured: During one week prior to baseline
Sleep quality and cycle (objective)
Participants will be provided with a Xiaomi® Smart Band 9 activity bracelet to monitor sleep quality. The device will record sleep cycle phases and data, as well as detailed data on heart rate and oxygen saturation.
Measured: During one week prior to baseline
Waist-hip ratio
Will be calculated using the waist circumference (in centimeters) and the hip circumference (in centimeters)
Measured: Baseline
Hip circumference
Hip circumference will be assed in centimeters (cm)
Measured: Baseline
Waist circumference
Waist circumference will be assed in centimeters (cm)
Measured: Baseline
Sleep quality (subjective)
Sleep quality will also be assessed by completing the Spanish version of the questionnaire Pittsburgh Sleep Quality Index (PSQI). This questionnaire consists of 24 items, of which 19 questions are self-assessed, while the remaining five are questions assessed by the patient's partner or roommate (the latter are not scored and are used only as clinical information). The total score ranges from 0-21 points, where a higher score indicates a worse subjective quality of sleep.
Measured: During one week prior to baseline
Heart rate variability
By monitoring the heart rate of the participants, heart rate variability will be assessed, which involves the variation of the time intervals between beats (R-R intervals) and which is shown to be a useful tool in the control of the patient's health since it is an estimator of the balance between the activity of the sympathetic and parasympathetic autonomic nervous system . To evaluate heart rate variability, a polar H10 band and heart rate monitor (Polar Electro Oy, Kempele, Finland) and a mobile application, specifically Elite HRV will be used. Heart rate variability will be monitored daily for the week prior to the initial assessment visits. To do this, participants will be instructed to take the measurement the first 5 minutes as soon as they wake up and on an empty stomach.
Measured: During one week prior to baseline
Stress levels
The level of perceived stress will be assessed through the perceived stress questionnaire (PSQ). This questionnaire consists of 30 items and is carried out autonomously in the presence of the evaluator (score goes from 0 to 120 points, with higher score indicating more perceived stress levels). In addition, the Perceived Stress Scale (Perceived Stress Scale (PSS)) in its version of 14 items that are carried out in a self-administered way (score goes from 0 to 56, with higher scores indicating more stress levels).
Measured: Baseline
Plasma testosterone/cortisol ratio
Plasma testosterone/cortisol ratio using ELISA kits. Fasting venous blood samples will be collected from the antecubital vein into EDTA-treated vacutainers and centrifuged at 1500g for 10 minutes. Plasma will then undergo a second centrifugation at 2500g for 15 minutes and be stored in cryogenic vials at -80ºC. Sample collection will be performed by a qualified nurse. Testosterone will be measured using the Invitrogen™ High Sensitivity Competitive ELISA Kit (Life Technologies; sensitivity: 2.97 pg/mL; range: 317.0-8440.5 pg/mL). Cortisol will be assessed with the Invitrogen™ Cortisol Competitive ELISA Kit (Life Technologies; sensitivity: 27.6 pg/mL; range: 8.5-23.8 µg/mL).
Measured: Baseline
Nutritional habits
Adherence to the Mediterranean diet will be assessed through the Mediterranean Diet Quality Index in childhood and adolescence (KIDMED) questionnaire. This quiz It consists of 16 questions that evaluate adherence to this diet in children and young people (from 2 to 24 years old) and can be performed self-administered or conducted by an interviewer. The score goes from -4 to 12, with higher score indicating better adherence to Mediterranean diet.
Measured: Baseline
Handgrip strength
Handgrip strength will be assessed using the hand-held Jamar® Plus Smart Dynamometer (Patterson Medical Ltd., Sammons Preston, Nottinghamshire, UK). Manual grip strength will be recorded on both limbs and the dynamometer will be adjusted to hand size prior to testing. The participant's elbow should be in 90° flexion and the forearm fully supported on a table.
Measured: Baseline
Gas exchange analysis
The values of mean and peak gas exchange (ml·kg-1·min-1) during a stress test. The gas analyzer that will be used in this study (Cortex Metalyzer 3B, Leipzig, Germany).
The basal metabolic rate (ml·kg-1·min-1) will be determined by recording the variables mentioned above for 15 minutes in supine position.
Measured: Baseline
Cardiovascular response
The values of mean and peak heart rate (beats per minute) will be assessed using a polar H10.
Measured: Baseline
Excess Post-exercise Oxygen Consumption
The Excess Post-exercise Oxygen Consumption (EPOC) post-exercise will be recorded on ml·kg-1·min-1. This will be calculated every minute for 12 min after the end of the exercise.
Measured: Baseline
Weight
Weight will be assess on kilograms (kg)
Measured: Baseline
Height
Height will be assess on centimeters (cm)
Measured: Baseline
Body surface area
Weight and height will be combined to report body surface area (BSA) in kg·cm-1
Measured: Baseline
Bioimpedance
The NUTRILAB bioimpedance device (AKERN Srl, Florence, Italy) will be used. This non-invasive method measures the body's resistance and reactance of the body to the passage of a low-intensity electric current and enables the determination of various body parameters. Bioimpedance provides accurate data on body composition. Users will be instructed to remove all metal-containing objects and remain in a supine position on a couch during the measurements, with the legs in 45° abduction, the shoulders in 30° abduction relative to the center of the body and the hands in pronation. After cleaning the skin with alcohol, two adhesive electrodes (Biatrodes Akern Srl, Florence, Italy) will be placed on the surface of the right hand and two on the right foot. The measurement results will be given in different unit measures depending on the specific variable assessed.
Measured: Baseline
Cognitive performance
Cognitive performance will be assessed through the questionnaire Frontal Assessment Battery (FAB). This questionnaire allows for rapid assessment of executive function through six tests that correspond to each specific cognitive or behavioral domain related to the frontal lobes. The scores ranges from 0 to 18 where higher scores indicating better cognitive function.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2025
- Study start16 Jun 2025
- Primary completion31 Oct 2025
- Study completion31 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Healthy Young AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 31 participants (actual)
Sponsor and investigators
- Lead sponsor
- European University Miguel de Cervantes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Simone Lista, PhD, Principal investigator, Miguel de Cervantes European UniversitySusana López-Ortiz, PhD, Study chair, Miguel de Cervantes European University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07032168
- Sponsor's protocol ID
- PI-DOC010-NEUROACTIVE
- Acronym
- NEUROACTIVE
- Status last verified
- Mar 2026
- First submitted
- 26 May 2025
- Last updated
- 9 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hurtado-Pomares M, Juarez-Leal I, Company-Devesa V, Sanchez-Perez A, Peral-Gomez P, Espinosa-Sempere C, Valera-Gran D, Navarrete-Munoz EM. Psychometric properties of the Spanish version of the Frontal Assessment Battery (FAB-E) and normative values in a representative adult population sample. Neurologia (Engl Ed). 2024 Oct;39(8):694-700. doi: 10.1016/j.nrleng.2022.09.004. Epub 2022 Oct 7.
PubMed 36216225Benito PJ, Alvarez-Sanchez M, Diaz V, Morencos E, Peinado AB, Cupeiro R, Maffulli N; PRONAF Study Group. Cardiovascular Fitness and Energy Expenditure Response during a Combined Aerobic and Circuit Weight Training Protocol. PLoS One. 2016 Nov 10;11(11):e0164349. doi: 10.1371/journal.pone.0164349. eCollection 2016.
PubMed 27832062Jarvinen L, Lundin Petersdotter S, Chaillou T. High-intensity resistance exercise is not as effective as traditional high-intensity interval exercise for increasing the cardiorespiratory response and energy expenditure in recreationally active subjects. Eur J Appl Physiol. 2022 Feb;122(2):459-474. doi: 10.1007/s00421-021-04849-4. Epub 2021 Nov 19.
PubMed 34799752Perrotta AS, Jeklin AT, Hives BA, Meanwell LE, Warburton DER. Validity of the Elite HRV Smartphone Application for Examining Heart Rate Variability in a Field-Based Setting. J Strength Cond Res. 2017 Aug;31(8):2296-2302. doi: 10.1519/JSC.0000000000001841.
PubMed 28195974Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65. No abstract available.
PubMed 8598068Concheiro-Moscoso P, Groba B, Alvarez-Estevez D, Miranda-Duro MDC, Pousada T, Nieto-Riveiro L, Mejuto-Muino FJ, Pereira J. Quality of Sleep Data Validation From the Xiaomi Mi Band 5 Against Polysomnography: Comparison Study. J Med Internet Res. 2023 May 19;25:e42073. doi: 10.2196/42073.
PubMed 37204853Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM, Aznar S. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011 Apr;14(3):347-53. doi: 10.1017/S1461145710000738. Epub 2010 Jul 7.
PubMed 20604989Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2001 Jan;2(1):24-32. doi: 10.1038/35049004.
PubMed 11253356Gomez-Pinilla F, Tyagi E. Diet and cognition: interplay between cell metabolism and neuronal plasticity. Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):726-33. doi: 10.1097/MCO.0b013e328365aae3.
PubMed 24071781Walsh R. Lifestyle and mental health. Am Psychol. 2011 Oct;66(7):579-92. doi: 10.1037/a0021769.
PubMed 21244124
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of Lifestyle Factors, Cardiorespiratory Fitness, and Body Composition on Plasma BDNF and pTau217 Levels and Cognitive Function in Healthy Young Adults
- ClinicalTrials.gov ID
- NCT07032168
- Acronym / sponsor ID
- NEUROACTIVE / PI-DOC010-NEUROACTIVE
- Conditions
- Healthy Young Adults
- Keywords
- Neuroplasticity, Lifestyle, Healthy young adults, Plasma biomarkers
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 31 participants (actual)
- Lead sponsor
- European University Miguel de CervantesUniversity, hospital or other
- Study start
- 16 Jun 2025 (actual)
- Primary completion
- 31 Oct 2025 (actual)
- Study completion
- 31 Oct 2025 (actual)
- First posted
- 22 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lifestyle play a key role in modulating brain health by directly influencing a number of key biological processes, such as neuroplasticity, neurogenesis, and regulation of biomarkers associated with cognitive decline. Factors such as physical activity, diet, sleep quality, stress management, and body composition have been shown to have a significant impact on neuroprotection and cognitive performance. These factors not only contribute to maintaining metabolic and functional balance in the body, but are also linked to the expression of biomarkers such as brain-derived neurotrophic factor (BDNF) and Tau protein phosphorylated at the amino acid threonine 217 (PTau217), which are essential for the maintenance of neuronal health and the prevention of neurodegenerative diseases. In this sense, a healthy lifestyle, characterized by regular physical activity, a balanced diet, good quality sleep, low stress levels and adequate body composition, can act as a protective factor against cognitive decline from early stages of life.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Healthy young adults | – | –Healthy young adults (18-24 years old) |
Who may qualify
- Ages
- 18 to 24 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Healthy young adults, between 18 and 24 years old.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Plasma biomarkers
Time frame: Baseline
Plasma concentrations of BDNF and pTau217 will be assessed using ELISA kits. Fasting venous blood samples will be collected by a qualified nurse from the antecubital vein into EDTA-treated vacutainers and centrifuged at 1500g for 10 minutes. Plasma will then undergo a second centrifugation at 2500g for 15 minutes and be stored in cryogenic vials at -80ºC. BDNF will be measured using the Human/Rat BDNF ELISA Kit (Proteintech Europe; sensitivity: 0.1 pg/mL; range: 12.5-800 pg/mL). PTau217 will be measured using the Human Phosphorylated Tau 217 ELISA Kit (GenoChem World; sensitivity: 0.1 pg/mL; range: 0.8-40 pg/mL).
19 secondary outcomes
Physical activity levels
Time frame: During one week prior to baseline
Sleep quality and cycle (objective)
Time frame: During one week prior to baseline
Waist-hip ratio
Time frame: Baseline
Hip circumference
Time frame: Baseline
Waist circumference
Time frame: Baseline
Sleep quality (subjective)
Time frame: During one week prior to baseline
Heart rate variability
Time frame: During one week prior to baseline
Stress levels
Time frame: Baseline
Plasma testosterone/cortisol ratio
Time frame: Baseline
Nutritional habits
Time frame: Baseline
Handgrip strength
Time frame: Baseline
Gas exchange analysis
Time frame: Baseline
Cardiovascular response
Time frame: Baseline
Excess Post-exercise Oxygen Consumption
Time frame: Baseline
Weight
Time frame: Baseline
Height
Time frame: Baseline
Body surface area
Time frame: Baseline
Bioimpedance
Time frame: Baseline
Cognitive performance
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2026.
- Results publication: PubMed 36216225Hurtado-Pomares M, Juarez-Leal I, Company-Devesa V, Sanchez-Perez A, Peral-Gomez P, Espinosa-Sempere C, Valera-Gran D, Navarrete-Munoz EM. Psychometric properties of the Spanish version of the Frontal Assessment Battery (FAB-E) and normative values in a representative adult population sample. Neurologia (Engl Ed). 2024 Oct;39(8):694-700. doi: 10.1016/j.nrleng.2022.09.004. Epub 2022 Oct 7.
- Results publication: PubMed 27832062Benito PJ, Alvarez-Sanchez M, Diaz V, Morencos E, Peinado AB, Cupeiro R, Maffulli N; PRONAF Study Group. Cardiovascular Fitness and Energy Expenditure Response during a Combined Aerobic and Circuit Weight Training Protocol. PLoS One. 2016 Nov 10;11(11):e0164349. doi: 10.1371/journal.pone.0164349. eCollection 2016.
- Results publication: PubMed 34799752Jarvinen L, Lundin Petersdotter S, Chaillou T. High-intensity resistance exercise is not as effective as traditional high-intensity interval exercise for increasing the cardiorespiratory response and energy expenditure in recreationally active subjects. Eur J Appl Physiol. 2022 Feb;122(2):459-474. doi: 10.1007/s00421-021-04849-4. Epub 2021 Nov 19.
- Results publication: PubMed 28195974Perrotta AS, Jeklin AT, Hives BA, Meanwell LE, Warburton DER. Validity of the Elite HRV Smartphone Application for Examining Heart Rate Variability in a Field-Based Setting. J Strength Cond Res. 2017 Aug;31(8):2296-2302. doi: 10.1519/JSC.0000000000001841.
- Results publication: PubMed 8598068Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65. No abstract available.
- Results publication: PubMed 37204853Concheiro-Moscoso P, Groba B, Alvarez-Estevez D, Miranda-Duro MDC, Pousada T, Nieto-Riveiro L, Mejuto-Muino FJ, Pereira J. Quality of Sleep Data Validation From the Xiaomi Mi Band 5 Against Polysomnography: Comparison Study. J Med Internet Res. 2023 May 19;25:e42073. doi: 10.2196/42073.
- Results publication: PubMed 20604989Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM, Aznar S. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011 Apr;14(3):347-53. doi: 10.1017/S1461145710000738. Epub 2010 Jul 7.
- Results publication: PubMed 11253356Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2001 Jan;2(1):24-32. doi: 10.1038/35049004.
- Results publication: PubMed 24071781Gomez-Pinilla F, Tyagi E. Diet and cognition: interplay between cell metabolism and neuronal plasticity. Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):726-33. doi: 10.1097/MCO.0b013e328365aae3.
- Results publication: PubMed 21244124Walsh R. Lifestyle and mental health. Am Psychol. 2011 Oct;66(7):579-92. doi: 10.1037/a0021769.
- Individual participant dataSharing planned: No
Related trials for Healthy Young Adults
Recruiting
Effects of Red Panax Ginseng Supplementation on Cognitive Performance and Emotional Well-Being in Young Healthy Adults
Mental Acuity
Recruiting
Development of a Real-time Controller to Estimate Walking Performance Using a Bilateral Ankle Exoskeleton
Healthy Young Adults
Recruiting
Yoga vs. Stretching-Strengthening: Physical Fitness in Sedentary Young Adults
Sedentary Lifestlye, Exercise
Recruiting
Recovery After Fatigue in Young Athletes: Comparison Between TECAR Therapy and Cycle Ergometer"
Muscle Fatigue, Healthy Adult
RecruitingPhase 3
Weight Gain Prevention in Adolescents and Young Adults
Healthy Volunteers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Simone Lista, PhD principal investigator
Miguel de Cervantes European University
Susana López-Ortiz, PhD study chair
Miguel de Cervantes European University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy Young Adults, run by European University Miguel de Cervantes at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma biomarkers (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07032168, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2026.